LUNG CANCER

The FDA granted Breakthrough Device Designation for RaDaR assay, a personalized liquid biopsy assay that tracks a set of up to 48 tumor-specific variants in patients with exceptional sensitivity.

Results from the phase CANOPY-2 clinical trial of canakinumab in combination with docetaxel as treatment of advanced or metastatic non–small cell lung cancer did not yield a favorable survival outcome.

The FDA has granted approval to the VENTANA ALK CDx Assay as a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who may be eligible for treatment with the recently approved ALK inhibitor lorlatinib.

Corey J. Langer, MD, discusses treatment options for a patient with non–small cell lung cancer based on the clinical trial research.

The FDA has expanded the approval for lorlatinib to include an indication for the first-line treatment of patients with ALK-positive non–small cell lung cancer.

Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.

Pembrolizumab has been withdrawn from the United States market as a treatment option for patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.

The FDA has expanded the use of PD-L1 IHC 22C3 pharmDx assay to include the diagnosis of patients with non-small cell lung cancer, announced the developer, Agilent Technologies, Inc.

The FDA has granted approval to cemiplimab-rwlc, for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression, as determined by an FDA-approved test. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation, and the tumors must not have EGFR, ALK, or ROS1 aberrations.

Final analysis results from the phase 3 IMpower110 trial show the benefit of atezolizumab over chemotherapy in a non–small cell lung cancer subgroup.

n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.

For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.

The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.

Kartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.

Kartik Konduri, MD, describes the phase 2 basket trial of lurbinectedin in the treatment of extensive-stage small cell lung cancer.

Kartik Konduri, MD, discusses treatment options for extensive-stage small cell lung cancer.

Kartik Konduri, MD, evaluates the case of a 68-year-old woman with extensive-stage small cell lung cancer.

Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.

The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive non–small cell lung cancer with acquired RET fusions.

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

The FDA has granted an accelerated approval to tepotinib for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a MET exon 14 skipping alteration.

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.

Patient-reported outcomes outcomes from the Check-Mate 743 trial demonstrated improved symptom burden and maintained overall health status with the use of nivolumab/ipilimumab over chemotherapy, in patients with unresectable malignant pleural mesothelioma.